Trial reportCannabis and cannabinoid research2021
A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures.
Trial report in Cannabis and cannabinoid research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound-Indication Matching and Precision Neurotherapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Review
- The phytocannabinoid cannabidivarin alleviates cognitive and social behaviour deficits in the sub-chronic phencyclidine rat model of relevance for schizophrenia.Journal of psychopharmacology (Oxford, England) · 2025Article
- Recent HPLC-UV Approaches for Cannabinoid Analysis: From Extraction to Method Validation and Quantification Compliance.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Medical cannabis: From research breakthroughs to shifting public perceptions and ensuring safe use.Integrative medicine research · 2024Review
- Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders.Biomolecules · 2024Review
- The Development of Cannabinoids as Therapeutic Agents in the United States.Pharmacological reviews · 2024Review
- Clinical Outcome Data of Children Treated with Cannabis-Based Medicinal Products for Treatment Resistant Epilepsy-Analysis from the UK Medical Cannabis Registry.Neuropediatrics · 2023Article
- Advances and Challenges of Cannabidiol as an Anti-Seizure Strategy: Preclinical Evidence.International journal of molecular sciences · 2022Review
- Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research.Biomolecules · 2022Review
- Nicotinamide Adenine Dinucleotide (NAD+) and Enkephalinase Inhibition (IV1114589NAD) Infusions Significantly Attenuate Psychiatric Burden Sequalae in Substance Use Disorder (SUD) in Fifty Cases.Current psychiatry research and reviews · 2022Article
- Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial.Epilepsia · 2022Article
- Expert advice for prescribing cannabis medicines for patients with epilepsy-drawn from the Australian clinical experience.British journal of clinical pharmacology · 2022Review
- Observational study of medical marijuana as a treatment for treatment-resistant epilepsies.Annals of clinical and translational neurology · 2022Observational
- Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.